A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting

Purpose: Despite triple antiemetic therapy use for breast cancer patients receiving emetogenic chemotherapy, nausea remains a clinical challenge. We evaluated adding olanzapine (5 mg) to triple therapy on nausea control in patients at high personal risk of chemotherapy-induced nausea and vomiting (C...

全面介绍

书目详细资料

Principais autores:	M. Clemons, G. Dranitsaris, M. Sienkiewicz, S. Sehdev, T. Ng, A. Robinson, M. Mates, T. Hsu, S. McGee, O. Freedman, V. Kumar, D. Fergusson, B. Hutton, L. Vandermeer, J. Hilton
格式:	Artigo
语言:	Inglês
出版:	Elsevier 2020-12-01
丛编:	Breast
主题:	Breast cancer Chemotherapy-induced nausea and vomiting Risk model Olanzapine
在线阅读:	http://www.sciencedirect.com/science/article/pii/S0960977620302083
标签:	添加标签 没有标签, 成为第一个标记此记录!